Chu Yi, Iida Shinichiro, Lund Donald D, Weiss Robert M, DiBona Gerald F, Watanabe Yoshimasa, Faraci Frank M, Heistad Donald D
Cardiovascular Center and Department of Internal Medicine, University of Iowa Roy J. and Lucille A. Carver College of Medicine, Iowa City, Iowa 52242, USA.
Circ Res. 2003 Mar 7;92(4):461-8. doi: 10.1161/01.RES.0000057755.02845.F9. Epub 2003 Jan 23.
Oxidative stress may contribute to hypertension. The goals of this study were to determine whether extracellular superoxide dismutase (ECSOD) reduces arterial pressure in spontaneously hypertensive rats (SHR) and whether its heparin-binding domain (HBD), which is responsible for cellular binding, is necessary for the function of ECSOD. Three days after intravenous injection of an adenoviral vector expressing human ECSOD (AdECSOD), mean arterial pressure (MAP) decreased from 165+/-4 mm Hg (mean+/-SE, n=7) to 124+/-3 mm Hg (n=7) in adult anesthetized SHR (P<0.01) but was not altered in normotensive Wistar-Kyoto rats. Cardiac output was not changed in SHR 3 days after AdECSOD. Gene transfer of ECSOD with deletion of the HBD (AdECSODDeltaHBD) had no effect on SHR MAP, even though plasma SOD activity was greater after AdECSODDeltaHBD than after AdECSOD. Immunohistochemistry revealed intense staining for ECSOD in blood vessels and kidneys after AdECSOD but not after AdECSODDeltaHBD. Impaired relaxation of the carotid artery to acetylcholine in SHR was significantly improved after AdECSOD. Cumulative sodium balance in SHR was reduced by AdECSOD compared with AdECSODDeltaHBD. Gene transfer of ECSOD also reduced MAP in conscious SHR, although the effect was not as profound as in anesthetized SHR. In summary, gene transfer of ECSOD, with a strict requirement for its HBD, reduces systemic vascular resistance and arterial pressure in a genetic model of hypertension. This reduction in arterial pressure may be mediated by vasomotor and/or renal mechanisms.
氧化应激可能导致高血压。本研究的目的是确定细胞外超氧化物歧化酶(ECSOD)是否能降低自发性高血压大鼠(SHR)的动脉血压,以及其负责细胞结合的肝素结合域(HBD)对于ECSOD的功能是否必要。在成年麻醉的SHR中,静脉注射表达人ECSOD的腺病毒载体(AdECSOD)三天后,平均动脉压(MAP)从165±4 mmHg(平均值±标准误,n = 7)降至124±3 mmHg(n = 7)(P<0.01),但在正常血压的Wistar-Kyoto大鼠中未发生改变。AdECSOD处理三天后,SHR的心输出量未改变。删除HBD的ECSOD基因转移(AdECSODDeltaHBD)对SHR的MAP没有影响,尽管AdECSODDeltaHBD处理后的血浆SOD活性高于AdECSOD处理后。免疫组织化学显示,AdECSOD处理后血管和肾脏中ECSOD染色强烈,而AdECSODDeltaHBD处理后则没有。AdECSOD处理后,SHR颈动脉对乙酰胆碱的舒张功能受损得到显著改善。与AdECSODDeltaHBD相比,AdECSOD降低了SHR的累积钠平衡。ECSOD基因转移也降低了清醒SHR的MAP,尽管其效果不如麻醉的SHR显著。总之,对其HBD有严格要求的ECSOD基因转移可降低高血压遗传模型中的全身血管阻力和动脉血压。动脉血压的这种降低可能是由血管舒缩和/或肾脏机制介导的。